Patents by Inventor Joshua VEATCH

Joshua VEATCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell-based neoantigen vaccines and uses thereof
    Patent number: 11723962
    Abstract: The present disclosure relates to immune cells that express an exogenous neoantigen and an immunogenicity enhancer, or to T cells that express an exogenous neoantigen, and their use in treating a disease or disorder, such as cancer for tumor associated neoantigens. Related expression constructs, kits, host cells, pharmaceutical compositions, and methods are also provided.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 15, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Stanley R. Riddell, Joshua Veatch
  • IMMUNOTHERAPY TARGETING KRAS OR HER2 ANTIGENS
    Publication number: 20210340201
    Abstract: Binding proteins and high affinity recombinant T cell receptors (TCRs) specific for KRAS G12V or Her2-ITD neoantigens are provided herein. Compositions and recombinant host cells encoding and/or expressing the binding proteins and/or high affinity recombinant TCRs are also provided. The compositions and recombinant host cells may be used to treat a subject having non-small cell lung cancer (NSCLC), colorectal cancer, pancreas cancer, ovarian cancer, breast cancer, biliary tract cancer, an indication wherein a KRAS G12V neoantigen is a therapeutic target, or an indication wherein a Her2-ITD neoantigen is a therapeutic target. Related vaccines, vaccine therapies, and vaccination regimens are also provided.
    Type: Application
    Filed: August 21, 2019
    Publication date: November 4, 2021
    Inventors: Joshua VEATCH, Stanley R. RIDDELL
  • BRAF-SPECIFIC TCRS AND USES THEREOF
    Publication number: 20210238250
    Abstract: The present disclosure provides binding proteins, such as TCRs, that specifically bind various tumor associated antigens (including human BRAFV600E epitope), cells expressing such antigen specific binding proteins, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells express BRAFV600E, such as in cancer.
    Type: Application
    Filed: August 10, 2018
    Publication date: August 5, 2021
    Inventors: Joshua VEATCH, Stanley R. RIDDELL, Sylvia LEE
  • BRAF-SPECIFIC TCRS AND USES THEREOF
    Publication number: 20200223899
    Abstract: The present disclosure provides binding proteins, such as TCRs, that specifically bind various tumor associated antigens (including human BRAFV600E epitope), cells expressing such antigen specific binding proteins, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells express BRAFV600E, such as in cancer.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 16, 2020
    Inventors: Joshua VEATCH, Stanley R. RIDDELL, Sylvia LEE
  • CELL-BASED NEOANTIGEN VACCINES AND USES THEREOF
    Publication number: 20190224236
    Abstract: The present disclosure relates to immune cells that express an exogenous neoantigen and an immunogenicity enhancer, or to T cells that express an exogenous neoantigen, and their use in treating a disease or disorder, such as cancer for tumor associated neoantigens. Related expression constructs, kits, host cells, pharmaceutical compositions, and methods are also provided.
    Type: Application
    Filed: May 4, 2017
    Publication date: July 25, 2019
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Stanley R. RIDDELL, Joshua VEATCH